22 Jul Scribe Therapeutics
David Parrot, Chief Financial Officer
Oct. 5 | 5:15pm | FLW Ballroom G
Alameda, CA
(Private)
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard-of-care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key lipid drivers of ASCVD. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence PCSK9 and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to protective effects of beneficial human genetics.